Friday, June 19, 2026

Medical condition

Cell Therapy

Cell Therapy is a medical condition tracked by NovaPharmaNews. Browse the latest pharmaceutical industry coverage and developments.

Latest Cell Therapy news

Cencora-Kite Agreement: A New Era for CAR T-cell Therapy Commercialization
AnalysisCAR T-cell therapiesJun 3, 2026

Cencora-Kite Agreement: A New Era for CAR T-cell Therapy Commercialization

The Cencora-Kite agreement marks a significant shift in CAR T-cell therapy commercialization, leveraging Cencora's distribution expertise to streamline patient access and reduce operational complexities. This collaboration aims to accelerate the delivery of critical therapies like Yescarta and Tecartus.

Dr. Sarah Mitchell
Expression Therapeutics Receives FDA Fast Track and Rare Pediatric Disease Designations for Hemophilia A Stem Cell Therapy
NewsApr 29, 2026

Expression Therapeutics Receives FDA Fast Track and Rare Pediatric Disease Designations for Hemophilia A Stem Cell Therapy

Expression Therapeutics gains dual FDA designations for investigational autologous stem cell therapy targeting hemophilia A, advancing to Phase 2 trials.

James Chen, PharmD
Miracell's SMART M-CELL Stem Cell Therapy Shows Cognitive Improvement in Severe Alzheimer's Patients
NewsAlzheimer's Disease/Neurodegenerative DisordersApr 25, 2026

Miracell's SMART M-CELL Stem Cell Therapy Shows Cognitive Improvement in Severe Alzheimer's Patients

Miracell reports positive Phase 2 results for SMART M-CELL CD34+ stem cell therapy showing cognitive improvement in moderate to severe Alzheimer's patients.

Dr. Natalie Hughes
FDA Approves First Cell Therapy for Treatment-Resistant MS
NewsNeurologyApr 21, 2026

FDA Approves First Cell Therapy for Treatment-Resistant MS

The FDA has approved AHSCT, the first cell therapy for treatment-resistant multiple sclerosis, marking a significant advancement in MS treatment options.

Dr. Sarah Mitchell
UCB Acquires Neurona Therapeutics for NRTX-1001 Epilepsy Cell Therapy in $XXX Million Deal
NewsEpilepsyApr 18, 2026

UCB Acquires Neurona Therapeutics for NRTX-1001 Epilepsy Cell Therapy in $XXX Million Deal

UCB announces acquisition of Neurona Therapeutics and lead epilepsy cell therapy NRTX-1001, currently in Phase I/II trials for treatment-resistant epilepsy patients.

Dr. Sarah Mitchell
FDA Approves Omisirge: New Allogeneic Stem Cell Therapy for Hematologic Cancers
Newshematologic malignanciesApr 3, 2026

FDA Approves Omisirge: New Allogeneic Stem Cell Therapy for Hematologic Cancers

The FDA has approved Omisirge, an innovative allogeneic stem cell therapy designed to treat hematologic cancers, marking a significant advancement in cancer care.

Dr. Sarah Mitchell
CAR-T Cell Therapy Advancements and FDA Regulatory Pathways 2024
AnalysisHematologic MalignanciesApr 1, 2026

CAR-T Cell Therapy Advancements and FDA Regulatory Pathways 2024

Discover the latest advancements in CAR-T cell therapy for cancer, including FDA regulatory pathways and their impact on treatment options in 2024.

Dr. Sarah Mitchell